Genmab and Bionomics to co-develop human antibodies for angiogenesis targets
Genmab and Bionomics, announced today that they will collaborate to create and develop fully human antibodies to angiogenesis targets identified by Bionomics. Under the terms of the collaboration agreement, the two companies will share equally in the resea
Copenhagen, Denmark and Adelaide, Australia; March 11, 2002 Genmab A/S and Bionomics Limited , announced today that they will collaborate to create and develop fully human antibodies to angiogenesis targets identified by Bionomics.
Under the terms of the collaboration agreement, the two companies will share equally in the research and development costs and the commercial rights and returns from antibody products they co-develop.
The joint research effort will focus initially on two angiogenesis targets identified and patented by Bionomics with the potential for further targets to be added in the future.
Genmab, a European and US-based company, with a market capitalization of around US$500 million is a leader in developing fully human antibodies. Bionomics is a leading Australian biotech company, with more than 230 genes from its research areas of angiogenesis, breast cancer and epilepsy covered by patent applications. Through its collaboration with the Hanson Institute, Bionomics has access to a novel model for rapidly identifying genes critical to the angiogenesis process.
Genmab will use its fully human antibody technology together with its broad antibody development capabilities of biologic assays and animal disease models, to generate and test fully human antibodies to these novel disease targets. Bionomics will screen antibodies generated by Genmab using its novel angiogenesis model and animal disease models to enable the selection of the most appropriate antibody for development. (...)
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
